The Sunlight Experiment

Compound Monograph

Esculetin

Esculetin (aesculetin, 6,7-dihydroxycoumarin) is the aglycone of esculin — a catechol-type dihydroxycoumarin of chicory, Mexican tarragon and ash bark. Its preclinical research centres on antioxidant/Nrf2 activity, anti-inflammatory action (NF-κB plus its signature 5-lipoxygenase inhibition) and apoptosis across tumour cell lines, with no human trials of the isolate. It is not a warfarin-type anticoagulant nor the hepatotoxic fragrance "coumarin."

Work in progress

Classification

Esculetin is a coumarin, part of the phenolics class. Antioxidant compounds built around one or more phenol rings — the flavonoids, tannins, phenolic acids, coumarins, and pigments behind much of a plant's protective chemistry.

Phenolics Coumarins

Where Does It Come From? (7)

Esculetin is a naturally occurring coumarin, found in Chicory, Mexican tarragon — aerial parts, Ash bark and 4 other sources. It is well tolerated orally (low toxicity).

Artemisia capillarisAsh barkChicoryCramp BarkHorse Chestnut — as its glucoside esculinMany plants as the aglycone of esculinMexican tarragon — aerial parts

Pharmacology & Research

Esculetin (aesculetin, 6,7-dihydroxycoumarin) is the aglycone of esculin — esculin is esculetin 6-O-glucoside, and gut β-glucosidase releases esculetin as the better-absorbed, generally active moiety, so esculetin is the effector of much of esculin’s in-vivo activity. Its ortho-dihydroxy (catechol) arrangement makes it a stronger intrinsic antioxidant than the mono-hydroxy coumarins, and its most distinctive mechanism is a historic one: it is a classic inhibitor of 5-lipoxygenase. Two discipline points (as for scopoletin): it is a 6,7-dihydroxycoumarin, not a 4-hydroxycoumarin/warfarin-type anticoagulant, and it is not the hepatotoxic fragrance “coumarin.” All evidence is preclinical.

What the evidence supports
  • A strong antioxidant with a signature enzyme target: catechol radical scavenging plus Nrf2/HO-1 induction, and well-characterised 5-lipoxygenase inhibition that sets it apart from esculin/scopoletin/umbelliferone 3,5Reference 32022Activation of Nrf2 by esculetin mitigates inflammatory responses through suppression of NF-κB signalling in RAW 264.7 cellsView study →Reference 51983Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesisView study →.
  • The honest headline: no human trials of the isolate; the anticancer, antidiabetic and hepatoprotective data are cell/rodent only, and much of the antioxidant signal is class-shared catechol chemistry 1,4Reference 12024ReviewTherapeutic potential of esculetin in various cancer types (review)View study →Reference 42024ReviewAntioxidant and anti-inflammatory effects of esculin and esculetin (review)View study →.
Evidence by indicationStrength of support
Antioxidant / Nrf2Shaky
40%
Anti-Inflammatory & 5-LipoxygenaseShaky
38%
AnticancerShaky
32%
AntidiabeticShaky
26%
HepatoprotectiveShaky
24%
1. Antioxidant / Nrf2

Esculetin’s catechol (6,7-dihydroxy) arrangement makes it a stronger direct scavenger than its mono-hydroxy siblings, and it activates the Keap1–Nrf2 pathway to raise SOD/GPx/glutathione 3,4Reference 32022Activation of Nrf2 by esculetin mitigates inflammatory responses through suppression of NF-κB signalling in RAW 264.7 cellsView study →Reference 42024ReviewAntioxidant and anti-inflammatory effects of esculin and esculetin (review)View study →, including Nrf2-mediated neuroprotection in a rat cerebral ischemia-reperfusion model 14Reference 142024AnimalEsculetin attenuates cerebral ischemia-reperfusion injury and protects neurons through Nrf2 activation in ratsView study →.

Gap: the mechanism is class-shared catechol chemistry with no in-vivo human antioxidant readout, and esculetin is rapidly conjugated in vivo (see pharmacokinetics) 2,4Reference 22022Pharmacological and therapeutic applications of esculetinView study →Reference 42024ReviewAntioxidant and anti-inflammatory effects of esculin and esculetin (review)View study →.

2. Anti-inflammatory & 5-lipoxygenase

This is esculetin’s most distinctive mechanism: it is a classic, potent inhibitor of arachidonate 5-lipoxygenase and leukotriene (LTB₄/5-HETE) biosynthesis in human leukocytes and platelets 5,6Reference 51983Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesisView study →Reference 61982Selective inhibition of platelet lipoxygenase by esculetinView study →, and it also restrains NF-κB and lowers TNF-α/IL-1β/IL-6 3Reference 32022Activation of Nrf2 by esculetin mitigates inflammatory responses through suppression of NF-κB signalling in RAW 264.7 cellsView study →.

Gap: the lipoxygenase data are decades-old in-vitro enzyme/cell studies and the in-vivo anti-inflammatory work is rodent-only, with no human isolate trials 5,6Reference 51983Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesisView study →Reference 61982Selective inhibition of platelet lipoxygenase by esculetinView study →.

3. Anticancer

Esculetin induces mitochondrial/caspase apoptosis in human leukemia cells 7Reference 72001Induction of apoptosis by esculetin in human leukemia cellsView study →, antiproliferative G1 arrest and apoptosis in pancreatic cancer by directly binding KEAP1 8Reference 82016Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1View study →, and ER-stress/ROS-mediated apoptosis in colon cancer cells 9Reference 92015Esculetin induces apoptosis in human colon cancer cells by inducing endoplasmic-reticulum stressView study →, with a 2024 review cataloguing activity across many tumour types 1Reference 12024ReviewTherapeutic potential of esculetin in various cancer types (review)View study →.

Gap: entirely in-vitro/xenograft, at high effective concentrations, with no clinical oncology data 1,8Reference 12024ReviewTherapeutic potential of esculetin in various cancer types (review)View study →Reference 82016Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1View study →.

4. Antidiabetic

In streptozotocin-diabetic rats, oral esculetin restored antioxidant enzymes and protected hepatic and renal tissue from hyperglycemia-mediated oxidative damage 10Reference 102013AnimalProtective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic ratsView study →.

Gap: a single-lab rodent cluster with no clinical translation 10Reference 102013AnimalProtective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic ratsView study →.

5. Hepatoprotective

Esculetin ameliorated high-fat-diet hepatic fibrosis via an Akt/PI3K/FoxO1 pathway 11Reference 112017Esculetin ameliorates hepatic fibrosis in high-fat-diet-induced non-alcoholic fatty liver disease by regulation of the FoxO1-mediated pathwayView study → and reduced CCl₄-induced hepatic apoptosis and oxidative stress in rats 12Reference 122011AnimalEsculetin ameliorates carbon-tetrachloride-mediated hepatic apoptosis in ratsView study →.

Gap: model-specific rodent data only 11,12Reference 112017Esculetin ameliorates hepatic fibrosis in high-fat-diet-induced non-alcoholic fatty liver disease by regulation of the FoxO1-mediated pathwayView study →Reference 122011AnimalEsculetin ameliorates carbon-tetrachloride-mediated hepatic apoptosis in ratsView study →.

Mechanisms

Target / pathwayEffectRelevant to
Arachidonate 5-lipoxygenase (also platelet LOX)inhibited (low-µM); ↓ LTB₄, 5-HETEanti-inflammatory (signature mechanism)
NF-κB (IκBα–p65)suppressed; ↓ TNF-α/IL-1β/IL-6anti-inflammatory
Keap1 / Nrf2 → HO-1, SOD, GPx, GSHactivatedantioxidant / cytoprotection / neuroprotection
Catechol (6,7-diOH) direct scavengingROS/RNS quenchedantioxidant
Mitochondrial apoptosis, ER stress, KEAP1 bindingpro-apoptotic in tumour linesanticancer
Esculin (6-O-glucoside) → β-glucosidase → esculetinhydrolysed to the active aglyconepharmacokinetic link to esculin

Pharmacokinetics

Esculetin is the aglycone of esculin and is better absorbed than the parent glucoside — dietary esculin must first be cleaved by gut-microbial β-glucosidase to esculetin before appreciable absorption 1,13Reference 12024ReviewTherapeutic potential of esculetin in various cancer types (review)View study →Reference 132021AnimalOral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in ratsView study →. Even so, esculetin’s own systemic exposure is short: a rat study found low oral bioavailability with rapid clearance, dominated by extensive phase-II glucuronidation (mainly at the C-7 hydroxyl), so free esculetin plasma levels are brief and much of the circulating drug is conjugated 13Reference 132021AnimalOral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in ratsView study →. Net: rapid conjugation, short free-drug exposure and no human pharmacokinetics of the isolate — with the loop back to esculin, where glucosylation lowers absorption but microbial β-glucosidase regenerates esculetin as the effector.

Clinical trials

There are no human clinical trials of isolated esculetin for any indication; all pharmacology is preclinical.

CompletedPlannedTerminatedPreclinical
—(none, isolate)——Substantial

Last checked: July 2026.

Toxicity & Safety

Esculetin’s [low] flag is deliberately lower than esculin’s [moderate], and justified: esculetin is not the named toxic principle of a plant classed as poisonous (that is esculin, the reason raw horse chestnut is not eaten), it is widely distributed in edible plants, and it is dosed orally at ~10–40 mg/kg in rodents without reported lethality 10,11Reference 102013AnimalProtective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic ratsView study →Reference 112017Esculetin ameliorates hepatic fibrosis in high-fat-diet-induced non-alcoholic fatty liver disease by regulation of the FoxO1-mediated pathwayView study →. Mirroring the scopoletin/esculin discipline, it is a 6,7-dihydroxycoumarin, not a 4-hydroxycoumarin — it does not carry warfarin’s mechanism, and the “coumarins thin the blood” claim does not apply; it is also not the hepatotoxic fragrance “coumarin.” One honest interaction caveat: esculetin inhibits platelet/leukocyte lipoxygenase and has preclinical antiplatelet signals 6Reference 61982Selective inhibition of platelet lipoxygenase by esculetinView study → — this is lipoxygenase-mediated, not anticoagulation, but a theoretical additive caution with antiplatelet drugs is reasonable to note.

Pregnancy & lactation

Avoid. No reproductive-safety data exist for the isolate; as a bioactive coumarin with preclinical antiplatelet/enzyme-inhibitory activity and no human exposure data, default to avoidance in pregnancy and lactation.

Dosage

There is no established human dose — esculetin has never been given to humans as an isolate. Preclinical figures (~10–40 mg/kg oral in rodent diabetes/liver models) are experimental research doses, not recommendations, and no safe self-administration guidance can be given.

References

  1. (2024). Therapeutic potential of esculetin in various cancer types (review). Oncology Letters. https://pubmed.ncbi.nlm.nih.gov/38774454/
  2. (2022). Pharmacological and therapeutic applications of esculetin. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/36293500/
  3. (2022). Activation of Nrf2 by esculetin mitigates inflammatory responses through suppression of NF-κB signalling in RAW 264.7 cells. Molecules. https://pubmed.ncbi.nlm.nih.gov/36014382/
  4. (2024). Antioxidant and anti-inflammatory effects of esculin and esculetin (review). Experimental and Therapeutic Medicine. https://pubmed.ncbi.nlm.nih.gov/38682114/
  5. (1983). Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochimica et Biophysica Acta. https://pubmed.ncbi.nlm.nih.gov/6411127/
  6. (1982). Selective inhibition of platelet lipoxygenase by esculetin. Biochimica et Biophysica Acta. https://pubmed.ncbi.nlm.nih.gov/6814494/
  7. (2001). Induction of apoptosis by esculetin in human leukemia cells. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/11282109/
  8. (2016). Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1. Molecular Cancer. https://pubmed.ncbi.nlm.nih.gov/27756327/
  9. (2015). Esculetin induces apoptosis in human colon cancer cells by inducing endoplasmic-reticulum stress. Cell Biochemistry and Function. https://pubmed.ncbi.nlm.nih.gov/26439795/
  10. (2013). Protective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic rats. Biochimie. https://pubmed.ncbi.nlm.nih.gov/23079336/
  11. (2017). Esculetin ameliorates hepatic fibrosis in high-fat-diet-induced non-alcoholic fatty liver disease by regulation of the FoxO1-mediated pathway. Pharmacological Reports. https://pubmed.ncbi.nlm.nih.gov/28527877/
  12. (2011). Esculetin ameliorates carbon-tetrachloride-mediated hepatic apoptosis in rats. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/21747724/
  13. (2021). Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats. Xenobiotica. https://pubmed.ncbi.nlm.nih.gov/33949288/
  14. (2024). Esculetin attenuates cerebral ischemia-reperfusion injury and protects neurons through Nrf2 activation in rats. Brazilian Journal of Medical and Biological Research. https://pubmed.ncbi.nlm.nih.gov/39504067/